NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Alexion Pharmaceuticals Inc (ETR: AXP)

 
AXP Technical Analysis
4
As on 30th Oct 2017 AXP Share Price closed @ 110.70 and we RECOMMEND Sell for LONG-TERM with Stoploss of 114.07 & Strong Sell for SHORT-TERM with Stoploss of 118.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

AXP Share Price

Open 111.45 Change Price %
High 112.75 1 Day 0.00 0.00
Low 110.70 1 Week 0.00 0.00
Close 110.70 1 Month -9.50 -7.90
Volume 854 1 Year -3.80 -3.32
52 Week High 136.65 | 52 Week Low 86.80
 
ETR Germany Most Active Stocks
DTE 15.31 -2.11%
DBK 14.13 1.29%
EOAN 10.38 2.47%
CBK 11.88 0.93%
IFX 24.51 4.30%
LHA 28.21 2.96%
DAI 73.07 2.50%
BIR 0.24 0.00%
TKA 23.49 2.53%
MEO 29.18 0.00%
 
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
M3B 0.84 21.74%
CR8 7.33 20.16%
R3Q 0.12 20.00%
5M71 39.00 13.70%
WI4 1.12 13.13%
KU2 210.50 11.97%
SONA 35.85 11.75%
SONA 35.85 11.75%
ELG 27.09 11.53%
 
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
U9R 10.60 -24.56%
BIO 24.70 -11.41%
BIO 24.70 -11.41%
BIO 24.70 -11.41%
BIO 24.70 -11.41%
 
 
AXP
Daily Charts
AXP
Intraday Charts
Whats New @
Bazaartrend
AXP
Free Analysis
 
AXP Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE112.60
RESISTANCE111.82
SUPPORT109.58
SUPPORT108.80
SUPPORT0.00
SUPPORT0.00
 
AXP Target for Month September
4th UP TARGET142.78
3rd UP TARGET132.49
2nd UP TARGET126.13
1st UP TARGET119.77
1st DOWN TARGET101.63
2nd DOWN TARGET95.27
3rd DOWN TARGET88.91
4th DOWN TARGET78.62
 
AXP Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
AXP Target for Year 2020
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
AXP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
AXP Address
AXP
352 Knotter Drive
Cheshire, CT 06410
United States
Phone: 203-272-2596
Fax: 203-271-8198
 
AXP Latest News
 
Your Comments and Response on Alexion Pharmaceuticals Inc
 
AXP Business Profile
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
 
2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service